Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Perspectives
Open Access

Burden of Proof for Tolvaptan in ADPKD

Did REPRISE Provide the Answer?

Reem A. Mustafa and Alan S.L. Yu
CJASN July 2018, 13 (7) 1107-1109; DOI: https://doi.org/10.2215/CJN.00190118
Reem A. Mustafa
Division of Nephrology and Hypertension, Department of Internal Medicine and The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan S.L. Yu
Division of Nephrology and Hypertension, Department of Internal Medicine and The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alan S.L. Yu
  • Article
  • Info & Metrics
  • View PDF
Loading

Article Information

vol. 13 no. 7 1107-1109
DOI 
https://doi.org/10.2215/CJN.00190118
PubMed 
29653956

Published By 
American Society of Nephrology
Print ISSN 
1555-9041
Online ISSN 
1555-905X
History 
  • Published online July 6, 2018.

Article Versions

  • Earlier version (April 13, 2018 - 07:18).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2018 by the American Society of Nephrology

Author Information

  1. Reem A. Mustafa, and
  2. Alan S.L. Yu
  1. Division of Nephrology and Hypertension, Department of Internal Medicine and The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas
  1. Correspondence:
    Dr. Alan S.L. Yu, Department of Internal Medicine, The Jared Grantham Kidney Institute, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3018, Kansas City, KS 66160. Email: ayu{at}kumc.edu

Statistics from Altmetric.com

Article usage

Article usage: April 2018 to June 2022

AbstractFullPdf
Apr 201801181265
May 20180778146
Jun 2018049284
Jul 201801131360
Aug 20180771132
Sep 20180796117
Oct 20180849135
Nov 20180933129
Dec 20180893112
Jan 20190897113
Feb 20190801112
Mar 20190822110
Apr 20190967118
May 2019058370
Jun 2019043455
Jul 2019047057
Aug 2019054046
Sep 2019036657
Oct 2019036355
Nov 2019032477
Dec 2019026040
Jan 2020032336
Feb 2020034941
Mar 2020025436
Apr 2020014921
May 2020014315
Jun 2020014430
Jul 2020015427
Aug 2020016649
Sep 2020017019
Oct 2020018532
Nov 2020011919
Dec 2020013019
Jan 2021039060
Feb 2021014030
Mar 2021016723
Apr 2021013314
May 2021015118
Jun 2021014017
Jul 2021019018
Aug 2021013519
Sep 2021012734
Oct 202109340
Nov 202105828
Dec 202101058
Jan 2022012717
Feb 2022013112
Mar 2022010514
Apr 2022015019
May 202209429
Jun 202207920

Cited By...

  • 5 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 13 (7)
Clinical Journal of the American Society of Nephrology
Vol. 13, Issue 7
July 06, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Burden of Proof for Tolvaptan in ADPKD
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Burden of Proof for Tolvaptan in ADPKD
Reem A. Mustafa, Alan S.L. Yu
CJASN Jul 2018, 13 (7) 1107-1109; DOI: 10.2215/CJN.00190118

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Burden of Proof for Tolvaptan in ADPKD
Reem A. Mustafa, Alan S.L. Yu
CJASN Jul 2018, 13 (7) 1107-1109; DOI: 10.2215/CJN.00190118
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Introduction
    • Implications for Clinical Practice
    • Future Research
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • A Body Size–Adjusted Maximum Ultrafiltration Rate Warning Level Is Not Equitable for Larger Patients
  • Food Insecurity and Kidney Disease
  • What Is the Best Maintenance Therapy for ANCA Vasculitis?
Show more Perspectives

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • ADPKD
  • Benzazepines
  • Biological Phenomena
  • chronic kidney disease
  • clinical trial
  • Cysts
  • humans
  • kidney failure
  • chronic
  • polycystic kidney
  • autosomal dominant
  • tolvaptan
  • United States
  • urinary tract physiological phenomena

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire